The Ohio State University Cancer Research Center was established in 1973 and received National Cancer Institute designation in April 1976 as a comprehensive cancer center (OSUCCC). The patient care arm of the OSUCCC is the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. The center is known as the OSUCCC – James.
The OSUCCC – James is a founding member of the National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers that develops clinical practice guidelines to improve the quality of care.
The concentration of cancer research and patient care at the OSUCCC has led the OSUCCC – James to become one of only a few cancer centers awarded contracts by the NCI to conduct both phase I and phase II clinical trials on new NCI-sponsored anticancer drugs. Those trials take place in inpatient and outpatient facilities at the center.
Active Therapeutic Thoracic Trials – November 2017 include:
- Randomized, Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-Based Chemotherapy in Patients With Chemotherapy-Naive Stage IV, Non-Small Cell Lung Cancer
- Open-Label, Single-Arm, Phase II Study of Nivolumab in Combination With Ipilimumab as First- Line Therapy in Stage IV Non-Small Cell Lung Cancer
- Phase II, Fast Real-Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced, Non-Small Cell Lung Cancer (FRACTION-Lung)
- Randomized, Phase II Study Evaluating Pembrolizumab vs. Topotecan in the Second-Line Treatment of Patients With Small-Cell Lung Cancer
- Phase III, Randomized, Open-Label Study of Lorlatinib (PF-06463922) Monotherapy vs. Crizotinib Monotherapy in the First-Line Treatment of Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer
- Randomized, Phase II Study of Individualized Combined-Modality Therapy for Stage III Non- Small Cell Lung Cancer
- Randomized, Double-Blind, Placebo-Controlled Study of Erlotinib or PlaceboiIn Patients With Completely Resected Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer
- Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide